PURPOSE: The purpose of this study was to determine the ability of a commonly used fingerstick technology to identify individuals with abnormal blood levels of total cholesterol (TC), calculated low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and high-sensitivity C-reactive protein (hsCRP) compared with a standardized laboratory. METHODS: Participants (n = 250; mean age, 48.0 +/- 13.5 years; 66% female; 36% nonwhite) were eligible for primary prevention of cardiovascular disease (CVD). Blood lipids and hsCRP were measured simultaneously by (1) fingerstick analyzed by Cholestech LDX analyzers and (2) fresh venous blood that was analyzed by Columbia University General Clinical Research Center (GCRC) Core Laboratory. Pearson correlation coefficients, kappa, sensitivity, and specificity were calculated for fingerstick versus GCRC laboratory values for lipids and hsCRP. RESULTS: The correlations betweenfingerstick and core laboratory for TC, LDL-C, HDL-C, TG, and hsCRP were .91, .88, .77, .93, and .81, respectively (all p< .01). Sensitivity and specificity of the fingerstick to identify those with abnormal lipids and hsCRP > or = 1 mg/L were all > or = 75%. CONCLUSION: Fingerstick screening is accurate and has good clinical utility to identify persons with abnormal blood lipids and hsCRP at the point of care in a diverse population that is eligible for primary prevention of CVD. These results may not be generalizable to patients at high risk for CVD or who have known hyperlipidemia.
PURPOSE: The purpose of this study was to determine the ability of a commonly used fingerstick technology to identify individuals with abnormal blood levels of total cholesterol (TC), calculated low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and high-sensitivity C-reactive protein (hsCRP) compared with a standardized laboratory. METHODS:Participants (n = 250; mean age, 48.0 +/- 13.5 years; 66% female; 36% nonwhite) were eligible for primary prevention of cardiovascular disease (CVD). Blood lipids and hsCRP were measured simultaneously by (1) fingerstick analyzed by Cholestech LDX analyzers and (2) fresh venous blood that was analyzed by Columbia University General Clinical Research Center (GCRC) Core Laboratory. Pearson correlation coefficients, kappa, sensitivity, and specificity were calculated for fingerstick versus GCRC laboratory values for lipids and hsCRP. RESULTS: The correlations betweenfingerstick and core laboratory for TC, LDL-C, HDL-C, TG, and hsCRP were .91, .88, .77, .93, and .81, respectively (all p< .01). Sensitivity and specificity of the fingerstick to identify those with abnormal lipids and hsCRP > or = 1 mg/L were all > or = 75%. CONCLUSION: Fingerstick screening is accurate and has good clinical utility to identify persons with abnormal blood lipids and hsCRP at the point of care in a diverse population that is eligible for primary prevention of CVD. These results may not be generalizable to patients at high risk for CVD or who have known hyperlipidemia.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: James H Stein; Cynthia M Carlsson; Kristi Papcke-Benson; Jean A Einerson; Patrick E McBride; Donald A Wiebe Journal: Clin Chem Date: 2002-02 Impact factor: 8.327
Authors: Wayne Rosamond; Katherine Flegal; Gary Friday; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Michael Ho; Virginia Howard; Brett Kissela; Bret Kissela; Steven Kittner; Donald Lloyd-Jones; Mary McDermott; James Meigs; Claudia Moy; Graham Nichol; Christopher J O'Donnell; Veronique Roger; John Rumsfeld; Paul Sorlie; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Yuling Hong Journal: Circulation Date: 2006-12-28 Impact factor: 29.690
Authors: Annette Plüddemann; Matthew Thompson; Christopher P Price; Jane Wolstenholme; Carl Heneghan Journal: Br J Gen Pract Date: 2012-03 Impact factor: 5.386
Authors: O Schlager; A Hammer; A Willfort-Ehringer; M Fritsch; B Rami-Merhar; E Schober; K Nagl; A Giurgea; C Margeta; S Zehetmayer; G H Schernthaner; R Koppensteiner; M E Gschwandtner Journal: Diabetologia Date: 2012-02-26 Impact factor: 10.122
Authors: Daniel P Bailey; Lynne M Boddy; Louise A Savory; Sarah J Denton; Catherine J Kerr Journal: Eur J Pediatr Date: 2012-03-15 Impact factor: 3.183